Bio Summary:
Dr. Senthil Surya Balasubramanian is a highly qualified and accomplished medical professional specializing in cardiology. With a diverse educational background and extensive training, he has established himself as a specialist in non-invasive cardiology and advanced cardiac imaging. Dr. Balasubramanian has a strong foundation in internal medicine, followed by specialized training in cardiology, including a chief fellowship role.
Education:
- MBBS [Bachelor of Medicine and Surgery]
- Thanjavur Medical College, Thanjavur, India
- Tamilnadu Dr. MGR State Medical University, Chennai, India
- August 2005 – March 2011
Professional Journey:
Honors & Awards:
- Chief Cardiology Fellow, University of Chicago (Northshore Program)
- Various board certifications including ASE Echo Board and CNBC Nuclear Board
Research Focus:
Dr. Balasubramanian’s research primarily focuses on various aspects of cardiology, including interventional procedures, medical therapy, and imaging techniques. His contributions span a range of topics such as coronary artery disease, transcatheter aortic valve implantation, and the impact of specific medications on patient outcomes.
Publications Top Noted & Contributions:
Dr. Balasubramanian has actively contributed to the medical literature with several published articles. Notable publications include a meta-analysis comparing percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting, and research on transcatheter aortic valve implantation.
Kikuchi-Fujimoto disease presenting in a patient with SARS-CoV-2: a case report
- Authors: SD Racette, BA Alexiev, MP Angarone, A Bhasin, K Lima, LJ Jennings, et al.
- Journal: BMC Infectious Diseases
- Year: 2021
- Volume: 21, Issue: 1
- Pages: 1-4
A meta-analysis comparing percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in unprotected left main disease
- Authors: V Kodumuri, S Balasubramanian, A Vij, S Siddamsetti, A Sethi, et al.
- Journal: The American Journal of Cardiology
- Year: 2018
- Volume: 121, Issue: 8
- Pages: 924-933
Impact of Tafamidis on Survival in a Real World Community-Based Cohort
- Authors: K Hussain, V Macrinici, L Wathen, SS Balasubramanian, I Minga, et al.
- Journal: Current Problems in Cardiology
- Year: 2022
- Pages: 101358
Meta-analysis comparing dual antiplatelet therapy versus single antiplatelet therapy following transcatheter aortic valve implantation
- Authors: S Siddamsetti, S Balasubramanian, S Yandrapalli, A Vij, U Joshi, G Tang, et al.
- Journal: The American Journal of Cardiology
- Year: 2018
- Volume: 122, Issue: 8
- Pages: 1401-1408
Safety and efficacy of direct oral anticoagulants versus warfarin for atrial fibrillation in end-stage renal disease on hemodialysis: A meta-analysis of randomized control trials
- Authors: M Faisaluddin, N Alwifati, N Naeem, S Balasubramanian, B Narasimhan, et al.
- Journal: The American Journal of Cardiology
- Year: 2023
- Volume: 206
- Pages: 309-311
Author Metrics:
-
Citations:
28 citations by 28 documents
-
Documents:
8 documents
-
h-index:
3 (h-index is a measure of the productivity and citation impact of an author’s publications; in this case, it’s 3)
Research Timeline:
- Published meta-analysis on Percutaneous Coronary Intervention vs. Coronary Artery Bypass Grafting – April 2018
- Published meta-analysis on Dual Antiplatelet Therapy vs. Single Antiplatelet Therapy post Transcatheter Aortic Valve Implantation – October 2018
- Case report on Kikuchi-Fujimoto disease presenting in a patient with SARS-CoV-2 – August 2021
- Published study on the impact of Tafamidis on survival in a real-world community-based cohort – December 2022
- Meta-analysis on Direct Oral Anticoagulants vs. Warfarin for Atrial Fibrillation in End-Stage Renal Disease – September 2023
- National propensity-matched analysis on Surgical Outcomes of Septal Myectomy With and Without Mitral Valve Surgeries in Hypertrophic Cardiomyopathy – October 2023
- Review article on Multimodality Imaging in Aortic Stenosis: Beyond the Valve – July 2023
